Table 1 (A) Clinical and laboratory features of 52 IgAN patients, 22 non-IgAN patients [Membranous Nephropathy (MN) n = 11, Minimal Change Disease (MCD) n = 9 and Focal Segmental Glomerulosclerosis (FSGS) n = 2] and 7 Kidney Living Donors (KLD) included in the study. (B) Clinical and laboratory features of active proliferative Lupus Nephritis (LN) patients (Classes III/IV) used for IHC analysis. (C) The test cohort is made up of 51 IgAN patients, 23 non-IgAN patients (4 minimal change disease, 4 membranous nephropathy, 15 hypertensive disease or diabetic nephropathy), 17 patients with lupus nephritis (LN) or vasculitis (VS) and 14 Healthy Blood Donors (HBD).

From: Formalin-fixed paraffin-embedded renal biopsy tissues: an underexploited biospecimen resource for gene expression profiling in IgA nephropathy

 

A

Multicenter study cohort

B

IHC analysis

C

Test cohort

IgAN

Non-IgAN (MN/MCD/FSGS)

KLD

LN

IgAN

Non-IgAN

LN-VS

HBD

Number

52

11/9/2

7

6

51

23

17

14

Male/female

38/14

10/12

1/6

1/5

36/15

15/8

5/12

8/6

Age (years)

41.19 ± 13.00

47.85 ± 18.61

54.83 ± 13.75

45.00 ± 13.65

41.47 ± 14.73

61.25 ± 15.39

43.88 ± 15.46

43.96 ± 11.68

sCr (mg/dL)

1.32 ± 0.57

0.92 ± 0.34

0.96 ± 0.14

1.42 ± 0.98

1.62 ± 0.74

1.71 ± 1.01

1.18 ± 0.39

0.86 ± 0.19

eGFR (CKD-EPI)

73.5 ± 33.36

92.40 ± 28.21

82.20 ± 5.00

81.21 ± 29.24

64.57 ± 31.57

44.73 ± 25.59

52.7 ± 23.84

102.29 ± 25.19

Proteinuria (g/24 h)

1.97 ± 2.41

9.10 ± 6.93

n.d

1.44 ± 1.12

1.73 ± 1.64

6.70 ± 2.86

1.44 ± 0.62

n.d

Hypertension (%)

25%

14%

n.d

33%

41%

45%

30%

n.d

Follow-up (mean time in yrs)

6.64 ± 3.03

5.00 ± 3.66

n.d

n.d

7.89 ± 5.55

7.94 ± 5.49

n.d

n.d

  1. Data is expressed as mean ± standard deviation (SD); n.d. not determined; data refers to the time of Biopsy.
Back to article page